Mobile

This is an open-label, multicenter, nonrandomized Phase 1b study of oral administration of LY2157299 in combination with gemcitabine followed by a randomized, double-blind, Phase 2 study of oral admin...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-000211-64

This is an open-label, multicenter, nonrandomized Phase 1b study of oral administration of LY2157299 in combination with gemcitabine followed by a randomized, double-blind, Phase 2 study of oral administration of LY2157299 monohydrate in combination with gemcitabine versus gemcitabine plus placebo

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Phase 2: To compare overall survival (OS) in patients with Stage II-IV unresectable pancreatic cancer when treated with the combination of LY2157299 monohydrate and gemcitabine with that of gemcitabine plus placebo.

Critère d'inclusion

  • Phase 2: Advanced or Metastatic Unresectable Pancreatic Cancer

Liens